Bioavailability Genetics Protein 
Cloudbyz
MARCH 5, 2024
Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.
Delveinsight
JANUARY 7, 2021
It also slates to commence a Phase Ib trial of its second candidate, TERN-201, a vascular adhesion protein (VAP-1) inhibitor, with top-line data anticipated in the first half of 2022. Biotheranostics’ two PCR-based genetic tests are well established in the U.S.: Hologic acquires Biotheranostics for USD 230 Million.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
JULY 30, 2020
Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. A novel, brain penetrant, orally bioavailable and selective PPAR?
XTalks
AUGUST 30, 2022
A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?
Delveinsight
SEPTEMBER 8, 2021
The exact cause of SLE is unknown; however, factors such as sunlight and drugs may precipitate the condition, and many studies have revealed a complex genetic basis. Baricitinib, also known as LY3009104 or INCB028050 , is a novel orally bioavailable inhibitor of the tyrosine-protein kinase JAK1 or JAK2.
Roots Analysis
JANUARY 28, 2024
By analyzing large datasets from various sources, such as clinical trials, genetic data, and EHRs, big data analytics can help identify new potential drug candidates, accelerate the drug discovery process, and lead to the development of more effective and targeted medicines.
The Pharma Data
DECEMBER 9, 2020
Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. It’s like taking out the trash.
Expert insights. Personalized for you.
97 
Let's personalize your content